• Two patients wearing headphones and a healthcare provider in a white coat looking at their smartphones, framed by large quotation marks on a blue background

MATTER in Action: What Really Drives GLP-1 Patients to Direct-to-Patient Platforms

Published November 19, 2026 | 5 Minute Read

Key Takeaways

  • Awareness isn’t the barrier to GLP-1 direct-to-patient (DTP) adoption (96% of patients already know a platform exists, yet only 10% use one), making this say/do gap an ideal case study for application of Health Union’s MATTER framework.  
  • Looking beneath stated intent across three behavioral lenses reveals the real forces stalling growth: fear of losing their doctor, confusion over how DTP works, and post-fill isolation.  
  • Each diagnostic finding maps to a clear commercial lever: reassure patients on continuity of care, explain the process at the coverage-denial moment, and close the feedback loop with prescribers. 

Recent Articles

Woman using a laptop to research her health symptoms

Women Have the Symptoms. What They Need Is a Shared Language With Their Doctors.

Over half of women with endometriosis signs are undiagnosed. See how a shared vocabulary with HCPs can help close the women’s health gap.

The Rare Marketing Summit: Redefining the Commercial Model for Rare Disease, presented by Health Union and DTC Perspectives, over a view of the Boston skyline and waterfront

Health Union and DTC Perspectives Convene Biopharma Leaders at Inaugural Rare Marketing Summit to Tackle Complex Commercial Hurdles

Traditional market research tells healthcare brands what people do. When we launched our proprietary behavioral science framework, MATTER, our goal was to go further: to uncover why patients and providers act the way they do, and give commercial teams the exact levers to pull to drive change.

To see how MATTER works in practice, we applied it to our 2026 survey of 1,398 patients living with chronic conditions and 64 HCPs in which we asked about perceptions and behaviors regarding DTP pharmacy platforms. We focused specifically on GLP-1 medications, the one therapeutic category where DTP has achieved meaningful traction (accounting for 81% of all DTP users in our study, with 10% of GLP-1 fills going through DTP compared to 4% or less in other categories).

Read through a traditional lens, the top-line takeaway is predictable: Raise awareness.  Read through the MATTER framework, that exact same dataset shows why awareness spend would be wasted. 

  • Awareness isn’t the problem. While 96% of GLP-1 users already know a DTP platform exists, only 10% use one. 
  • To understand why the other 90% are staying away, and how to keep the 10% who convert, you have to look beneath stated intentions.

Let’s examine what our three MATTER framework lenses revealed about GLP-1 patients’ mindsets and motivations around DTP programs.

Lens 1: Mindset (Uncovering What Opens the Say/Do Gap)

Although 50% of non-DTP GLP-1 users said they would try a platform if their doctor recommended it, only 17% said they are likely to try one in the next 12 months, and 58% of fills remain at local retail pharmacies. MATTER’s Mindset lens uses behavioral science principles (including Dual-Process Theory and Fogg Motivation drivers) to diagnose why:

  • Concerns Outweigh Hope (Fogg Motivation): Patients are protecting a vital relationship. Nearly half (47%) want their own doctor to remain sole manager of their prescription, and only 28% expect DTP to cost less than retail (vs. 45% of active users). Prescribers share this anxiety, with 26% of PCPs, NPs, and PAs saying DTP harms continuity of care.
  • The Rational Case Isn’t Made (System 2): Unanswered doubts stall deliberate evaluation. Among non-users, 29% aren’t sure DTP offers the same pharmacist oversight, 27% doubt it saves money, and 23% worry about sharing health data.
  • Habit Wins by Default (System 1): Familiar routines require zero mental effort, and 35% of non-users are comfortable with their current pharmacy and don’t want a new system.

What This Changes for Marketers: Because the barrier is emotional and relational, more cost messaging alone won’t work. DTP platforms must position themselves as an extension of the patient’s own doctor, not a replacement.

Lens 2: Activation & Triggers (Confidence Comes Before the First Fill)

When motivation is mixed, friction kills conversion. MATTER’s Activation & Triggers lens evaluates perceived difficulty (Fogg Ability), Task-Initiation Self-Efficacy, and the cues (Prompts) that spark first-time action:

  • Low Mental Clarity Blocks Ability: A task feels hard when patients can’t picture the steps. While 96% of non-DTP GLP-1 users are aware of  a GLP-1 platform and 31% have visited one, only 23% understand how the model works. They want step-by-step mechanics, upfront price comparisons, and clarity on insurance or Medicare compatibility.
  • Users De-Risked the Decision First (Self-Efficacy): Before their first fill, active DTP users built confidence: 82% talked to their doctor, 57% compared drug costs, 50% confirmed eligibility criteria, and 50% checked side effects and interactions. Non-users haven’t built that footing.
  • The Doctor at the Coverage-Denial Moment (Prompts): Insurance denials drive 84% of HCP referrals to DTP. For patients, the physician is the catalyst: 70% of DTP GLP-1 users had their own doctor send the prescription, and 57% chose their platform on a doctor’s mention.

What This Changes for Marketers: Top-of-funnel awareness has done its job. Brands should shift spend toward demystifying the onboarding process and equipping prescribers right at the coverage-denial moment.

Lens 3: Experience & Retention (Protecting Loyalty Beyond the First Fill)

Right now, DTP platforms are winning on Friction-Reward Balance. Although out-of-pocket costs are higher among DTP users (82% of DTP GLP-1 users pay $100 or more per month vs. 28% of non-users), 80% are highly likely to stay because the rewards outweigh that cost, driven by transparent pricing (64% rate it clearer than retail, vs. 32% of non-users) and reliable delivery (86% satisfaction). 

Traditional research would stop at that 80% retention score. MATTER’s Experience & Retention lens goes deeper, using Maintenance Self-Efficacy and Self-Determination Theory to spot hidden vulnerabilities before churn happens:  

  1. Price-Tethered Autonomy: Nearly half (48%) of DTP users would shop around even if satisfied (vs. 28% of non-users), meaning loyalty rests heavily on price.
  1. Post-Fill Isolation (Maintenance Self-Efficacy): Over a third (34%) of users engage with no platform features beyond the fill. As one user noted, “I’ve been on my own to manage the medication.”
  1. A Broken Prescriber Feedback Loop: Only 8% of HCPs often receive clinical notes back from DTP providers, and 50% have found a clinical conflict needing intervention. Leaving referring doctors in the dark threatens the main channel driving adoption.

What This Changes for Marketers: Transparent cash pricing wins the first fill, but sustaining retention requires ongoing support beyond delivery and a reliable feedback loop to the prescribing doctor.

From Insight to Action: Pulling the Right Levers

Reading our DTP study through the MATTER framework turns broad market observations into three concrete, testable commercial levers:

MATTER Lens

Diagnostic Finding

Commercial Lever to Pull

Mindset

(Reassure)

Fear of losing their doctor, pharmacist/data doubts, and retail habit dampen non-user intent. Frame DTP as doctor-led: Lead with “Your doctor prescribes, we deliver,” highlight pharmacist oversight, and give PCPs continuity-of-care talking points.

Activation & Triggers

(Explain & Prompt)

Only 23% understand how DTP works; adopters built confidence with their own research and their doctor at the coverage-denial moment. Shift spend to a 3-step explainer: Show that (1) your doctor sends the Rx, (2) you see the price before committing, and (3) it ships with pharmacist support. Give HCPs a coverage-denial script.

Experience & Retention

(Close the Loop)

Users plan to stay today, but 48% would shop around, 34% use no post-fill tools, and only 8% of HCPs regularly get notes back. Build post-fill value and EHR integration: Expand educational support (currently used by 41%) to cover side effects and Medicare bridges, and automate fill-status updates to the prescriber’s EHR.

Putting MATTER to Work for Your Brand

Because MATTER is modular, Health Union customizes which lenses we emphasize, and how deeply we probe, based on your specific commercial objectives. Whether you need to overcome prescriber hesitation, simplify onboarding, or protect adherence, MATTER moves your research past what stakeholders say so you can act on what truly drives them.

Ready to uncover the behavioral levers behind your brand’s growth opportunities? Connect with Health Union’s Insights team to see how MATTER can be tailored to your next research engagement.

(Study baseline: Fielded July 9 – August 3, 2026, among 1,398 chronic condition patients, including 423 on a GLP-1, plus 64 DTP-familiar prescribers across endocrinology, primary care, and NP/PAs.)

Recent Articles

Woman using a laptop to research her health symptoms

Women Have the Symptoms. What They Need Is a Shared Language With Their Doctors.

Over half of women with endometriosis signs are undiagnosed. See how a shared vocabulary with HCPs can help close the women’s health gap.

© 2026 Health Union, LLC. All rights reserved.